“The
Report Global Biosimilar Market Trends & Opportunities: 2015
Edition provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz”
Scope
of the Report
The report titled “Global
Biosimilar Market: Trends & Opportunities (2015 Edition)”
analyzes the global biologics market, with exhaustive discussion on
demand of Biosimilars with increase in patent expiry of innovator
drugs. The key market challenges recognized by the analysts and the
major trends biosimilar market are presented in the report. Further,
key manufacturers of Biosimilars like Sandoz, Teva, Hospira and Dr.
Reddy’s Lab are profiled in the report.
View Full Report at
http://www.marketresearchreports.biz/analysis/242914
Product
Coverage
- Recombinant Glycosylated Biosimilars (EPO,mAb,Follitropin)
- Humira, Enbrel, Remicade, Herceptin
- Recombinant Non-Glycosylated Biosimilars (Insulin,G-csf,Interferons,hGh)
- Company Coverage
- Sandoz(Novartis)
- Hospira
- Teva
- Dr. Reddy’s Lab
Executive
Summary
Rising budgetary pressures to
reduce healthcare expenditures, patent expiries of blockbuster drugs,
growing demand for cost-effective alternatives, increasing aging
population, conductive government initiatives and rising incidences
of various diseases are significant factors that are responsible for
the growth of global biosimilar market (2013 to 2018). On the other
hand stringent regulatory environment in some countries, high
manufacturing complexities, costs, and presence of low priced generic
drugs and high-entry barriers are considered to hinder the market
growth. Emerging pharmaceutical market and less stringent government
regulatory frameworks in few countries can provides some of the major
opportunities for biosimilars market. In addition, increased
collaboration between manufacturing companies and outsourcing of
biosimilar products are key trends for biosimilars market.
The biosimilar products market
is segmented into recombinant non-glycosylated proteins, recombinant
glycosylated proteins, and recombinant peptides. Globally there are
280 biosimilars in pipeline and their clinical trials are increasing
at a rate of 20% annually.
Download Detail Report With
Complete TOC at
http://www.marketresearchreports.biz/sample/sample/242914
The report titled “The
Global Biosimilar Market: Trends & Opportunities (2014-2018)”
provides an in-depth analysis of the growing Biosimilar Market with
detailed analysis of market sizing and growth, market share and
economic impact of the industry. The report also assesses the key
opportunities in the market and outlines the factors that are and
will be driving the growth of the industry. Growth of the overall
Biosimilars industry has also been forecasted for the period 2014-18,
taking into consideration the previous growth patterns, the growth
drivers and the current and future trends. Further, key players of
the industry like Sandoz, Teva, Hospira and Dr. Reddy’s Lab are
profiled.
Table
Of Content
1. EXECUTIVE SUMMARY
2. GLOBAL BIOSIMILAR MARKET
2.1 Overview of Biosimilar
Market
2.1.1 History
2.1.2 Prescription of
Biosimilars
2.1.3 Naming of Biosimilars
2.1.4 Determination of
Biosimilarity
2.1.5 Differences between
Biosimilar and Original Drugs
2.1.6 Manufacture of
Biosimilars
2.1.7 Safety, Efficacy,
Quality
2.1.8 Variability in
Biosimilars
2.1.9 Regulating Biosimilars
2.1.10 Approval Pathways of
Biosimilars
2.1.11 Market Segmentation by
Therapeutic Area
3. GLOBAL BIOSIMILAR MARKET:
SIZING AND GROWTH
3.1 Biosimilar Market Size:
2009-2013
3.2 Forecasted Biosimilar
market Size : 2014-2018
Related
Reports
Pharmaceutical excipients
refer to adjuvants and additives used for production of
pharmaceuticals and compounding of prescriptions. In addition to
active ingredients, pharmaceutical excipients are also contained in
pharmaceutical preparations after reasonable safety assessment.
China has launched more than
500 types of pharmaceutical excipients, far less than 1,500 types of
the United States and 3,000 types of Europe. By market size, gelatin
capsules, sucrose, starch, film-coated powder, 1,2-propylene glycol,
polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC),
microcrystalline cellulose, hydroxypropyl cellulose (HPC) and lactose
rank as the top 10 pharmaceutical excipients in China.
The Chinese recombinant
protein drug market has been expanding rapidly owing to the
improvement of demand rigidity, consumption ability and the like.
During 2005-2013, sales of recombinant protein drugs available in
Chinese sample hospitals grew at a CAGR of 19.1%, and it is projected
that China will see its actual demand for recombinant protein drugs
exceed RMB40 billion in 2014.
The start of recombinant
protein drugs in China is not late and common drugs are diversified
in variety, for example, recombinant human erythropoietin (rhEPO),
recombinant human granulocyte colony-stimulating factor (rhG-CSF) and
recombinant human interferon (rhIFN) have gained market approval in
the 1990s. Moreover, in 2013, domestic rhG-CSF, rhEPO andrecombinant
human growth hormone (rhGH) with price advantage took a respective
share of 82.1%, 88.5% and 90.2% in Chinese sample hospitals, and
recombinant human interleukin-2/11(rhIL-2/11) was fully localized.
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
E:
sales@marketresearchreports.biz
No comments:
Post a Comment